Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
Understand clinical trials, development strategy and regulatory pathways shaping drug approval.
Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.
By directly stimulating the visual cortex instead of relying on the retina or optic nerve, ReVision's FDA Breakthrough Device-designated implant could make vision restoration possible for millions of patients who have no existing treatment options.
Dr David Hayes explains why clinical research should be embedded early in cardiac device development and not treated as a late-stage compliance step.